Psyence Biomedical Ltd. (PBM)
| Market Cap | 844.85K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -51.16M |
| Shares Out | 16.70M |
| EPS (ttm) | -7.85 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,995,728 |
| Open | 0.0560 |
| Previous Close | 0.0541 |
| Day's Range | 0.0503 - 0.0560 |
| 52-Week Range | 0.0500 - 14.5500 |
| Beta | -0.42 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 22, 2024 |
About PBM
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in t... [Read more]
Financial Performance
Financial StatementsNews
Psyence Biomedical Announces Results from Annual and Special General Meeting, Share Consolidation and Receipt of Additional Staff Determination from Nasdaq
NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the voting results for each of the matters presented at the Compan...
Psyence Group Announces Closing of Previously Announced Disposal of its Stake in PsyLabs
PsyLabs develops and produces certified pharmaceutical-grade nature-derived psychedelics for applications in mental health and well-being
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustmen...
Psyence Biomed Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment Disorder in Palliative Care
Empax Center brings significant expertise in clinical trial execution for mental health and neurological conditions Psyence Biomed on track to begin recruitment this quarter, and to announce Adjustmen...
Psyence Biomed Provides Progress Update on PsyLabs E.U. Good Manufacturing Practices (GMP) Certified Active Pharmaceutical Ingredient (API) Development
PsyLabs to exclusively supply Psyence Biomed with high purity, pharmaceutical grade psilocybin for its second development indication, Alcohol Use Disorder, as previously announced PsyLabs to exclusive...
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical
TORONTO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group" or the "Company") (CSE: PSYG) hereby announces that it has entered into a debt-for-equity swap agreement (the "Debt Swap A...
Psyence Biomed Provides Update on Previously Announced Acquisition of Clairvoyant
NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence Biomed" or the "Company"), a developer of psilocybin-based therapeutics, today provided an update on its pre...
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs
PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being PsyLabs develops and produces certified pharmaceutical-grade natural ...
Psyence Biomed Enters into Agreement to Acquire Stake in PsyLabs
PsyLabs develops and produces certified pharmaceutical-grade natural psychedelics for applications in mental health and well-being PsyLabs develops and produces certified pharmaceutical-grade natural ...
Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
NEW YORK, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and ...
Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones
Initiated Phase IIb study of nature-derived psilocybin as a potential treatment for Adjustment Disorder in Palliative Care Expanded pipeline into Alcohol Use Disorder (AUD) and Substance Use Disorde...
Psyence Biomedical Ltd. Announces Receipt of Staff Delisting Determination from Nasdaq
NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on September 12, 2024, the Company received a staff determination letter (the “Determi...
Psyence Biomed Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment for Adjustment Disorder in Palliative Care
Patient screening to be initiated imminently; first subject expected to be randomized into the study in October Patient screening to be initiated imminently; first subject expected to be randomized in...
Psyence Biomed Announces the Signing of a Conditional Binding Term Sheet for the Acquisition of Psilocybin-Based Drug Developer Clairvoyant
Clairvoyant currently executing a fully randomized multi-country Phase IIb clinical trial evaluating a synthetic psilocybin candidate as a potential therapeutic for Alcohol Use Disorder (AUD)
Psyence Biomed Announces Registration Statement on Form F-1 for Up to $25 Million Equity Line of Credit with White Lion Capital, LLC, Declared Effective by SEC
NEW YORK, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that the registration statement pertaining to its previously annou...
Psyence Biomed to Present at the H.C. Wainwright 26th Annual Global Investment Conference, September 9th-11th, 2024
NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”), a developer of nature-derived psilocybin-based therapeutics, today announced that...
Optimi Health and Psyence Biomedical Sign Non-Binding Letter of Intent to Advance Global Psilocybin Drug Development
Vancouver, British Columbia and New York, New York--(Newsfile Corp. - August 13, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi"), a GMP-approved, Health Canada licensed ps...
Psyence Biomed Enters Into $25 Million Common Stock Purchase Agreement with White Lion Capital, LLC
NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced that it has entered into a $25 million common stock purchase agree...
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and w...
Psyence Biomed Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
Trial projected to be initiated shortly following receipt of drug product by trial sites NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Com...
Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that it received a notification letter dated June 27, 2024, from the Listings Qualifications...
Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase
NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that management will host 1x1 meetings with investors during the A.G....
Psyence Biomed Announces Phase IIb Clinical Trial Listing on the Australian New Zealand Clinical Trials Registry (ANZCTR)
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that details of its upcoming Phase IIb clinical trial of nature-der...
Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Psyence Group Inc ("Psyence Group") (CSE: PSYG), a life science biotechnology company pioneering the use of nature-derived psilocybin in mental health and ...